Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Timing of Second Generation ALK Inhibitors_ First Line vs. Treatment after Acquired Resistance [720p]
